A5006003315- Multiple Myeloma Research and Treatments
- Reproductive Biology and Fertility
- Protein Degradation and Inhibitors
- Cancer therapeutics and mechanisms
- Cutaneous lymphoproliferative disorders research
- Monoclonal and Polyclonal Antibodies Research
- Ovarian function and disorders
- Cancer Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Microbial infections and disease research
- Bacteriophages and microbial interactions
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cancer Risks and Factors
- Genomics and Phylogenetic Studies
- Family Support in Illness
- Reproductive Health and Technologies
- HIV/AIDS drug development and treatment
- Ubiquitin and proteasome pathways
- HER2/EGFR in Cancer Research
- CNS Lymphoma Diagnosis and Treatment
- Breast Cancer Treatment Studies
University of Rochester
2022-2023
Dana-Farber Cancer Institute
2019-2021
Memorial Sloan Kettering Cancer Center
2019-2021
Dana-Farber Brigham Cancer Center
2019
Michigan State University
2019
Brigham and Women's Hospital
2019
Carnegie Mellon University
2017
Recently, the benefit of adding daratumumab to proteasome inhibitor-based, 3-drug combination bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed multiple myeloma who underwent high-dose melphalan chemotherapy autologous hemopoietic cell transplant was assessed. Here, we examine addition second-generation carfilzomib, dexamethasone.To assess safety effectiveness carfilzomib-lenalidomide-dexamethasone-daratumumab therapy myeloma, in absence transplant.Clinical...
To (1) identify the major barriers premenopausal individuals face in accessing fertility care at time of gynecologic cancer diagnosis and (2) to assess patient experiences pertaining fertility.We distributed an online survey about goals patients ages 18-40 who had been treated for ovarian, endometrial, or cervical a single, large academic hospital. Descriptive statistics were used analyze results. Patients completed given option participate follow-up virtual interview. We conducted...
Dermal lymphatic invasion (DLI) with tumor emboli is a common pathologic characteristic of inflammatory breast cancer (IBC), although its presence not required for diagnosis. We examined whether documented DLI on skin biopsy was associated survival and time to recurrence or progression in IBC.A total 340 women enrolled the IBC Registry at Dana-Farber Cancer Institute between 1997 2019 were included this study. Kaplan-Meier curves multivariable Cox proportional hazards models used estimate...
Abstract Purpose: The pathologic hallmark of inflammatory breast cancer (IBC) is the presence tumor emboli within papillary and reticular dermis skin, termed dermal lymphatic invasion (DLI). DLI can be confirmed with a skin-punch biopsy in approximately 75% cases, but its not required for diagnosis IBC because variability affected areas. impact confirming by skin on clinical outcome unknown. We hypothesize that ability to confirm associated higher load consequently poorer disease prognosis....
287 Background: Individuals who have received treatment for gynecologic malignancy often reduced fertility options. However, there is a paucity of data on patient experience about this aspect their treatment. The primary objective study was to quantify individual wishes preservation and perceived barriers they may faced in pursuing preservation, if desired. Methods: An online survey 21 questions distributed 228 patients ages 18-40 at the time diagnosis with ovarian cancer, endometrial or...